![Albert Qin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 4 M $ al 31/07/2026
Albert Qin is currently the Chief Medical Officer at PharmaEssentia Corp., a position held since 2017.
Formerly, Dr. Qin was an Executive Officer and Chief Scientific Officer at SymBio Pharmaceuticals Ltd.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
PHARMAESSENTIA CORP. 0,03 % | 28/02/2026 | 109.314 ( 0,03 % ) | 4 M $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| PHARMAESSENTIA CORPORATION | Director Técnico/Científico/I+D | 13/01/2017 |
| Empresas | Cargo | Fin |
|---|---|---|
| SYMBIO PHARMACEUTICALS LIMITED | Director Técnico/Científico/I+D | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 2 |
|---|---|
SymBio Pharmaceuticals Ltd.
 SymBio Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutics for cancer and other related diseases | Health Technology |
PharmaEssentia Corp.
 PharmaEssentia Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells therapeutic products for the treatment of hematologic diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
